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Cancer control is not beyond us ... but 
could be if we don’t invest wisely
There must be a balanced investment portfolio in cancer control 
T
he 2015 World Cancer Day theme is “Not beyond 
us”. It is recognised worldwide that we need to 
invest wisely in areas of cancer control that will 
actually deliver the very best outcomes for patients and 
the community more broadly. The Choosing Wisely pro-
gram is an exemplar of large health systems optimising 
outcomes while disinvesting in practices that, at best, add 
cost and, at worst, add substantially to patients’ harms.1
“we urgently need an honest 
community conversation about 
the level of benefit that needs 
to be achieved”
Australia needs to invest wisely in cancer control, or the 
rate at which outcomes have improved in the past 30 
years will not be maintained.2,3 Action in three areas will 
guarantee better cancer outcomes across the population:
• Continuing to reduce the use of tobacco. In the 50th 
anniversary report of the United States Surgeon 
General (2014) outlining the relationship between 
cancer and smoking, a new relationship was high-
lighted: that people who continue to smoke even after 
a diagnosis of cancer have subsequent higher all-cause 
and cancer-specific mortality compared with people 
who ceased smoking at such a time.4 Efforts to reduce 
tobacco use need to be complemented by an increased 
focus on other lifestyle behaviours, such as physical 
activity and reducing body mass indices across the 
community.
• Having every Australian between the ages of 50 and 
75 years undertake regular 2-yearly faecal occult blood 
testing. Mortality from bowel cancer nationally would 
be reduced by more than 500 people each and every 
year, with improved outcomes being delivered by 
simpler and less costly treatments.5
• Reducing variations in clinical outcomes that are di-
rectly related to health facilities’ caseloads for proce-
dures. People with rarer cancers, such as oesophageal 
or pancreatic cancers, and sarcomas, should be treated 
in an institution with an adequate caseload and an ef-
fective multidisciplinary team.6 Simultaneously, effort 
is required to improve the local availability of thera-
pies with outcomes not affected by a volume–outcome 
relationship, including low-risk chemotherapy, colon 
cancer surgery and most radiotherapy. However, the 
full extent of variations in cancer outcomes in the 
Australian community will only be apparent when 
there is routine access to identified unit record level 
data from Medicare, the Pharmaceutical Benefits 
Scheme, population and clinical cancer registries, 
and the National Death Index.
By contrast, there is increasing pressure to invest in new 
therapies that have captured the imagination and hopes 
of many people but for which there are limited efficacy 
data and few effectiveness data. Despite the investments 
to date in targeted and biological therapies, the overall 
impact on population health outcomes has been limited.2
Once any new medication is introduced, it will be used: 
for longer periods of time; in a wider patient popula-
tion; at different doses; for a wider range of indications; 
and in people with a larger number of comorbidities. 
Another way to state this is that registration studies are 
likely to show better outcomes than can be achieved 
in the real-world use of the medication. Most of these 
new therapies will have harms that were not identi-
fied in the original registration studies, and we lack an 
adequate pharmacovigilance program to ensure a timely 
response to early signals of any emerging longer term 
toxicities, especially if the toxicity relates to amplification 
of a prevalent comorbidity.
There is also the assumption that an average increase in 
life expectancy is spread evenly across the population 
exposed to a new therapy. This is unlikely. For example, 
a small group of responders with markedly prolonged 
survival may mask premature mortality in others, even 
when the comparator arm may be best supportive care.7,8
As our investment in new, high-cost therapies increases 
and the benefits approach the asymptote, we urgently 
need an honest community conversation about the level 
of benefit that needs to be achieved (and to understand 
what is forgone) if we prioritise this expenditure. While 
parts of the pharmaceutical industry are comfortable with 
a willingness-to-pay model for pricing these therapies, at 
a systems level we must consider cost-effectiveness, not 
simply a right to access.9 Decisions to fund such thera-
pies require full disclosure of all trial data relating to 
the new therapy.
If there is a finite pool of resources for cancer control 
in Australia, then it is urgent we understand how best 
to invest those resources to improve population-wide 
cancer outcomes. It is human nature to put faith in new 
and emerging therapies; but when we have potential 
further gains from proven programs that have delivered 
better outcomes today, these are where the first call on 
resources should be.
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